Surrey Heartlands

Joint Formulary & PAD

Abatacept - Rheumatoid arthritis

You are here : Home > Formulary Search > Abatacept - Rheumatoid arthritis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Intravenous infusion
  • Subcutaneous injection (sc)
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
ICB
NICE
Restrictions / Comments :

Documentation

Guidelines (Local)
Rheumatoid Arthritis High cost immunomodulator drug pathway Apr-24.pdf
NICE Technology Appraisal
NICE TA375 - Biologics in Rheumatoid Arthritis - January 2016
NICE Technology Appraisal
NICE TA195 - Biologics for the treatment of Rheumatoid Arthritis after failure of a TNF inhibitor - August 2010
NICE Technology Appraisal
NICE TA715 - Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis - July 2021
Evidence Review
Biologics for treating moderate rheumatoid arthritis - NICE briefing - September 2021.pdf

PAD Profile

ChemicalSubstance :
Abatacept
Indication :
Rheumatoid arthritis
Group Name :
Keywords :
RA, Biologic, NICE, immunosuppressant, T-cell co-stimulation inhibitor, DMARD, Bdmard, Disease modulating, Rheumatology
Brand Names Include :
Orencia
Important Information :
Severe disease only. NON-FORMULARY for moderate disease
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Rheumatoid arthritis
Supporting Documents :
5

Other Indications

Below are listed other indications that Abatacept is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Rheumatoid arthritis.

Committee Recommendations (2)

03 Apr 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated rheumatoid arthritis pathways (moderate and severe).

01 Sep 21 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Abatacept is NON-FORMULARY for moderate disease.

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agrees with the recommendations made in NICE TA715.

Abatacept for moderately active Rheumatoid Arthritis was not recommended by NICE and will be given a NON-FORMULARY traffic light status for this indication. The current treatment pathway is attached below.